WO2015196299A1 - Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products - Google Patents
Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products Download PDFInfo
- Publication number
- WO2015196299A1 WO2015196299A1 PCT/CA2015/050599 CA2015050599W WO2015196299A1 WO 2015196299 A1 WO2015196299 A1 WO 2015196299A1 CA 2015050599 W CA2015050599 W CA 2015050599W WO 2015196299 A1 WO2015196299 A1 WO 2015196299A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- sodium citrate
- edta
- zinc
- zncl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 131
- 238000000034 method Methods 0.000 title claims description 16
- 230000032770 biofilm formation Effects 0.000 claims abstract description 58
- 239000002738 chelating agent Substances 0.000 claims abstract description 35
- 239000004599 antimicrobial Substances 0.000 claims abstract description 19
- 241000894006 Bacteria Species 0.000 claims abstract description 18
- 230000003115 biocidal effect Effects 0.000 claims abstract description 8
- 239000000499 gel Substances 0.000 claims abstract description 8
- 239000006071 cream Substances 0.000 claims abstract description 7
- 239000006210 lotion Substances 0.000 claims abstract description 7
- 239000003349 gelling agent Substances 0.000 claims abstract description 5
- 235000015110 jellies Nutrition 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 4
- 239000000344 soap Substances 0.000 claims abstract description 4
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 3
- 239000008274 jelly Substances 0.000 claims abstract 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 232
- 239000001509 sodium citrate Substances 0.000 claims description 231
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 231
- 239000011592 zinc chloride Substances 0.000 claims description 162
- 235000005074 zinc chloride Nutrition 0.000 claims description 70
- 230000002401 inhibitory effect Effects 0.000 claims description 68
- 239000000243 solution Substances 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 21
- 229960003085 meticillin Drugs 0.000 claims description 21
- 230000000845 anti-microbial effect Effects 0.000 claims description 18
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 16
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 16
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 14
- 239000011746 zinc citrate Substances 0.000 claims description 14
- 235000006076 zinc citrate Nutrition 0.000 claims description 14
- 229940068475 zinc citrate Drugs 0.000 claims description 14
- -1 NT A Chemical compound 0.000 claims description 13
- 241001299738 Malassezia pachydermatis Species 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 238000004140 cleaning Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 241000794282 Staphylococcus pseudintermedius Species 0.000 claims description 11
- 239000000645 desinfectant Substances 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims description 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 9
- 241000191967 Staphylococcus aureus Species 0.000 claims description 9
- 230000002924 anti-infective effect Effects 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 6
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 6
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 6
- 241000222122 Candida albicans Species 0.000 claims description 6
- 241000194032 Enterococcus faecalis Species 0.000 claims description 6
- 241000186779 Listeria monocytogenes Species 0.000 claims description 6
- 241000588770 Proteus mirabilis Species 0.000 claims description 6
- 241001138501 Salmonella enterica Species 0.000 claims description 6
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 6
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims description 6
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 6
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 6
- 230000000249 desinfective effect Effects 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000011576 zinc lactate Substances 0.000 claims description 6
- 235000000193 zinc lactate Nutrition 0.000 claims description 6
- 229940050168 zinc lactate Drugs 0.000 claims description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 5
- 241000295644 Staphylococcaceae Species 0.000 claims description 5
- 108010059993 Vancomycin Proteins 0.000 claims description 5
- 229940095731 candida albicans Drugs 0.000 claims description 5
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 229960003165 vancomycin Drugs 0.000 claims description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims description 5
- 229960001939 zinc chloride Drugs 0.000 claims description 5
- 108010062877 Bacteriocins Proteins 0.000 claims description 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 4
- 108010026206 Conalbumin Proteins 0.000 claims description 4
- 108010063045 Lactoferrin Proteins 0.000 claims description 4
- 102000010445 Lactoferrin Human genes 0.000 claims description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003889 eye drop Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 4
- 229940078795 lactoferrin Drugs 0.000 claims description 4
- 235000021242 lactoferrin Nutrition 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000001508 potassium citrate Substances 0.000 claims description 4
- 229960002635 potassium citrate Drugs 0.000 claims description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 4
- 235000011082 potassium citrates Nutrition 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 229960003600 silver sulfadiazine Drugs 0.000 claims description 4
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 229960003500 triclosan Drugs 0.000 claims description 4
- 150000003751 zinc Chemical class 0.000 claims description 4
- 239000011670 zinc gluconate Substances 0.000 claims description 4
- 235000011478 zinc gluconate Nutrition 0.000 claims description 4
- 229960000306 zinc gluconate Drugs 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 4
- 229960001763 zinc sulfate Drugs 0.000 claims description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 4
- 108010065152 Coagulase Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229940012356 eye drops Drugs 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 241000589875 Campylobacter jejuni Species 0.000 claims description 2
- 241000588923 Citrobacter Species 0.000 claims description 2
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 claims description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 2
- 108010067770 Endopeptidase K Proteins 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 108010053775 Nisin Proteins 0.000 claims description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 2
- 241000194054 Streptococcus uberis Species 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- WXBXVVIUZANZAU-HJWRWDBZSA-N cis-2-decenoic acid Chemical compound CCCCCCC\C=C/C(O)=O WXBXVVIUZANZAU-HJWRWDBZSA-N 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- PZZHMLOHNYWKIK-UHFFFAOYSA-N eddha Chemical compound C=1C=CC=C(O)C=1C(C(=O)O)NCCNC(C(O)=O)C1=CC=CC=C1O PZZHMLOHNYWKIK-UHFFFAOYSA-N 0.000 claims description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 2
- 210000002744 extracellular matrix Anatomy 0.000 claims description 2
- 229910052733 gallium Inorganic materials 0.000 claims description 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000004309 nisin Substances 0.000 claims description 2
- 235000010297 nisin Nutrition 0.000 claims description 2
- 239000002997 ophthalmic solution Substances 0.000 claims description 2
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 239000004300 potassium benzoate Substances 0.000 claims description 2
- 235000010235 potassium benzoate Nutrition 0.000 claims description 2
- 229940103091 potassium benzoate Drugs 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 229940115922 streptococcus uberis Drugs 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 229960000314 zinc acetate Drugs 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 101800004361 Lactoferricin-B Proteins 0.000 claims 1
- JYXGIOKAKDAARW-UHFFFAOYSA-N N-(2-hydroxyethyl)iminodiacetic acid Chemical compound OCCN(CC(O)=O)CC(O)=O JYXGIOKAKDAARW-UHFFFAOYSA-N 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- 108010064983 Ovomucin Proteins 0.000 claims 1
- 102000007327 Protamines Human genes 0.000 claims 1
- 108010007568 Protamines Proteins 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- XMSHRLOQLUNKSN-UHFFFAOYSA-N destosyl pyrazolate Chemical compound CC1=NN(C)C(O)=C1C(=O)C1=CC=C(Cl)C=C1Cl XMSHRLOQLUNKSN-UHFFFAOYSA-N 0.000 claims 1
- 229960002163 hydrogen peroxide Drugs 0.000 claims 1
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229940054534 ophthalmic solution Drugs 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 229950008679 protamine sulfate Drugs 0.000 claims 1
- 229940030998 streptococcus agalactiae Drugs 0.000 claims 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical class [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 222
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 45
- 238000002835 absorbance Methods 0.000 description 44
- 229910021645 metal ion Inorganic materials 0.000 description 28
- 238000009631 Broth culture Methods 0.000 description 22
- 239000013078 crystal Substances 0.000 description 22
- 239000002054 inoculum Substances 0.000 description 22
- 238000010186 staining Methods 0.000 description 22
- 230000003214 anti-biofilm Effects 0.000 description 16
- 244000005700 microbiome Species 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000009472 formulation Methods 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 230000002421 anti-septic effect Effects 0.000 description 7
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229940064004 antiseptic throat preparations Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 3
- 229910001958 silver carbonate Inorganic materials 0.000 description 3
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 3
- 229910000367 silver sulfate Inorganic materials 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- XIMLTUOVUPHQML-UHFFFAOYSA-K C(C)(=O)[O-].[Zn+2].S(=O)(=O)([O-])[O-].[Zn+2] Chemical compound C(C)(=O)[O-].[Zn+2].S(=O)(=O)([O-])[O-].[Zn+2] XIMLTUOVUPHQML-UHFFFAOYSA-K 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 229940009188 silver Drugs 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 102000007347 Apyrase Human genes 0.000 description 1
- 108010007730 Apyrase Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- GDSYPXWUHMRTHT-UHFFFAOYSA-N Epidermin Natural products N#CCC(C)(C)OC1OC(CO)C(O)C(O)C1O GDSYPXWUHMRTHT-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000002111 Eye Abnormalities Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 108010063293 cinnamycin Proteins 0.000 description 1
- QJDWKBINWOWJNZ-OURZNGJWSA-N cinnamycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H]3CNCCCC[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CS[C@H]4C)C(=O)N[C@@H](CS[C@H]2C)C(=O)N3)NC1=O)[C@@H](O)C(O)=O)C(O)=O QJDWKBINWOWJNZ-OURZNGJWSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010067071 duramycin Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 108010064962 epidermin Proteins 0.000 description 1
- CXTXHTVXPMOOSW-JUEJINBGSA-N epidermin Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSC[C@H](C(N[C@@H](CCCCN)C(=O)N1)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@H]1C(N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CS[C@H]1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)NCC(=O)N[C@H]1C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@H](C(N\C=C/SC2)=O)CSC1)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 CXTXHTVXPMOOSW-JUEJINBGSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010087689 lacticin 481 Proteins 0.000 description 1
- SFWLDKQAUHFCBS-WWXQEMPQSA-N lancovutide Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@@H](CCCCNC[C@H]4C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)N[C@H]([C@@H](SC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSC3C)CSC2)C(=O)N4)C)C(=O)N1)C(O)=O)[C@@H](O)C(O)=O)=O)C(C)C)C1=CC=CC=C1 SFWLDKQAUHFCBS-WWXQEMPQSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/14—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group; Thio analogues thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
- A01N37/04—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof polybasic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
- A61B3/125—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes with contact lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C11/00—Dental articulators, i.e. for simulating movement of the temporo-mandibular joints; Articulation forms or mouldings
- A61C11/005—Dental articulators, i.e. for simulating movement of the temporo-mandibular joints; Articulation forms or mouldings with tracing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention may relate to methods of using antimicrobial and antibiofilm compositions for personal care products. It further may relate to methods of formulating the compositions comprising chelating agents, zinc salts, antimicrobials and personal care acceptable excipients for applications in personal care products. More particularly, the invention may relate to an efficient method of delivering acceptable formulations containing two or more chelating agents and a zinc salt for personal care.
- Contact lenses are used by an increasing number of people as means of correcting vision and/or compensating for eye abnormalities. Contact lenses usually must be inserted and removed daily with cleaning and disinfection between each wearing that requires solutions and containers. During wear and normal handling of contact lenses, microorganisms can adhere to the contact lenses and contaminate the storage containers/solution. Then, microorganisms that multiplied in the storage containers/solution can transfer to the eyes via contact lenses and become a pathogen that may cause eye infection. Various solutions have been developed to clean these deposits and disinfect the containers .
- Solutions that wet the lenses before insertion in the eye are required for contact lenses. After the contact lenses are inserted in the eye, ophthalmic solutions for rewetting, lubricating, and/or enhancing the comfort of the contact lens wearer are sometimes applied to the eye by means of a drop dispenser. Solutions for improving the comfort of wearing soft contact lenses by being added directly to the contact lens in the eye typically contain viscosity enhancing agents, lubricants, surfactants, buffers, preservatives, and salts.
- Multipurpose solutions are popular because of the convenience of a single solution for cleaning, disinfecting and conditioning contact lenses immediately prior to insertion of the lens in the eye.
- Multipurpose solutions are also designed for use as a wetting agent, without rinsing, meaning that the solution must be ophthalmically safe for eye contact. This limits, to some extent, the type and concentration of both cleaning agents, biocides, antibacterials, and antibiofilm agents that can be employed in the solution as a preservative or disinfectant as these tendto be irritating to the eye. Additionally, the surface active agents must not inhibit the wetting or conditioning function of the solution.
- compositions with improved antibacterial and antibiofilm properties while maintaining or increasing the biocidal efficacy of the product without adversely affecting comfort or safety in terms of the level of toxicity to eye tissue. It is also desirable to have a composition that can be utilized as an eye drop, an eyewash solution, a contact lens care solution or a cleaning solution, a storing solution, a disinfectant, a cleaning-storing solution, and a cleaning disinfecting-storing solution.
- Pedicure, manicure, and podiatry instruments such as those for cleaning and scrubbing the feet and hands and containers for soaking the feet and hands, are typically reused many times for many different clients.
- biocides including antibacterials and antibiofilm solutions must be strong enough to be effective against a wide variety of bacteria, without adversely affecting comfort or safety of the client and the podiatrist or manicurist, in terms of the level of toxicity.
- the instant invention may provide compositions and methods for prevention, decontamination or treatment of personal care products, including eye drops, eyewash solution, contact lens care solution, contact lens cleaning solution, contact lens storing solution, contact lens disinfectant, contact lens cleaning- storing solution, and contact lens cleaning disinfecting-storing solution, contact lens containers, contact lenses, as well as podiatric, manicure and pedicure solutions, gels, creams, jellies, powders, pastes, lotions, soaps and cleaners.
- One embodiment of the invention may provide a composition comprising (a) one or more chelating agents, and (b) one or two metal ion salts.
- a composition of the invention comprises: (a) a small amount of at least two chelating agents, (b) a small amount of at least one metal ion salt, wherein the amount of each of components (a) and (b) is sufficient to form an effective anti-infective composition against bacterial infections in the personal care products.
- a composition of the invention comprises: (a) a small amount of at least two chelating agents, (b) a small amount of at least one metal ion salt, and (c) personal care acceptable excipients.
- Still another embodiment of the invention may provide an anti- infective composition comprising two chelating agents and one or two metal ion salts that are effective against bacteria and fungi causing infections through the personal care products.
- compositions of the invention may be for use against one or more infection-associated bacteria or yeasts selected from the group consisting of
- Methicillin-resistant Staphylococcus aureus MRSA
- Staphylococcus epidermidis Coagulase negative staphylococci
- VRE Vancomycin resistant Enterococci
- a further embodiment of the invention may provide an anti-infective composition comprising at least two chelating agents and one are two metal ion salts that are for use against bacteria and yeasts found in or with the personal care products.
- the chelating agent is between about 5000 mg /L and about
- the metal ion salt is between about 1000 mg/L and about 10000 mg/L of the composition.
- the chelating agents may be selected from the group consisting of EDTA,
- the metal ion salts may be selected from the group consisting of zinc chloride, zinc lactate, zinc citrate, zinc gluconate, zinc sulfate zinc acetate, silver ion or silver sulfadiazine, silver sulfate, silver nitrate, and silver carbonate.
- the chelating agents are EDTA and sodium citrate, and metal ion salt is zinc chloride or zinc sulfate.
- the EDTA may be present at about 10 mg/ml and sodium citrate may be present at about 10 mg/ml.
- the zinc chloride or zinc lactate may be present at about 1 mg/ml.
- the composition may further comprise one or more ingredients selected from the group consisting of: water, citrate buffer, citric acid, stabilizing agent, a flavoring agent, vitamins, minerals, herbals, a surfactant, an antimicrobial peptide, an antimicrobial and a pH adjuster.
- the antimicrobial preservatives can be selected from potassium sorbate, potassium benzoate, sodium benzoate and benzoic acid, and can, in particular be used in contact lens cleaning and disinfecting solutions.
- the antimicrobial preservative can be in a concentration ranging from 0.25 g/L to 3 g/L.
- the invention may also teach methods of preparing a suitable formulation for use with the personal care products in a variety of ways, for example in a disinfecting solution, a lotion, cream, a gel, a spray, a thermoreversible gel spray, and a paste.
- the invention further may teach methods of preparing suitable formulations for treating or impregnating personal care products, including contact lenses, contact lens containers, and manicure, pedicure and podiatry tools and containers.
- the formulations can also include natural or synthetic flavorings and coloring agents.
- Thickening agents can also be added to compositions of the invention such as guar gum, carbopol, polyethylene glycol, pluronic F-127, sodium alginate, carboxymethyl cellulose, xanthan gum and other personal care acceptable thickening agents.
- a composition of the invention can include antibiofilm enzymes (cellulase, beta- N- acetylgluconase, DispersinB, papain, DNase 1, etc.), antimicrobial peptides, antibiotics (gentamicin, ciprofloxacin, ampicillin, cefamendole nafate, rifambicin, etc.), antimicrobials (triclosan, chlorhexidine, quaternary ammonium compounds, silver, silver salts, etc.) and other antibiofilm compounds.
- antibiofilm enzymes cellulase, beta- N- acetylgluconase, DispersinB, papain, DNase 1, etc.
- antimicrobial peptides antibiotics (gentamicin, ciprofloxacin, ampicillin, cefamendole nafate, rifambicin, etc.), antimicrobials (triclosan, chlorhexidine, quaternary ammonium compounds, silver, silver salt
- the invention may also teach the use of liposomal or nanoparticle delivery systems that enhance the stability and efficacy of anti-infective compounds in the compositions.
- the invention may also teach personal care products treated or impregnated with a composition of the invention, such as a contact lens, a contact lens container, a hand washing container, a hand or foot scrubber, and a foot washing container.
- a composition of the invention such as a contact lens, a contact lens container, a hand washing container, a hand or foot scrubber, and a foot washing container.
- FIG. 1 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone and in combination on methicillin-resistant Staphylococcus aureus (MRSA) growth and biofilm formation
- FIG. 2 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.125 mg/ml) and ZnCl 2 (0.1 mg/ml) alone and in combination on methicillin-resistant Staphylococcus pseudintermedius (MRSP) growth and biofilm formation
- MRSP methicillin-resistant Staphylococcus pseudintermedius
- FIG. 3 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone and in combination on Pseudomonas aeruginosa growth and biofilm formation
- FIG. 4 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.062 mg/ml) and ZnCl 2 (0.1 mg/ml) alone and in combination on Listeria monocytogenes growth and biofilm formation
- FIG. 5 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 and EDTA + ZnCl 2 combinations on methicillin-resistant Staphylococcus aureus (MRSA) growth and biofilm formation
- MRSA methicillin-resistant Staphylococcus aureus
- FIG. 6 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.125 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on methicillin-resistant Staphylococcus pseudintermedius (MRSP) growth and biofilm formation
- MRSP methicillin-resistant Staphylococcus pseudintermedius
- FIG. 7 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml), and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2, and EDTA + ZnCl 2 combinations on Pseudomonas aeruginosa growth and biofilm formation
- FIG. 7 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml), and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2, and EDTA + ZnCl 2 combinations on Pseudomonas aeruginosa growth and biofilm formation
- FIG. 9 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Escherichia coli 0157:H7 growth and biofilm formation
- FIG. 10 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and in combination on Escherichia coli 0157:H7 growth and biofilm formation
- FIG. 11 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.125 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Staphylococcus epidermidis growth and biofilm formation
- FIG. 12 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.125 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Coagulase-negative Staphylococci (CoNS-42) growth and biofilm formation
- FIG. 13 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Streptococcus agalactiae ATCC 12386 growth and biofilm formation
- FIG. 14 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.125 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Klebsiella pneumoniae growth and biofilm formation
- FIG. 15 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.125 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Acinetobacter baumannii growth and biofilm formation
- FIG. 16 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Stenotrophomonas maltophilia growth and biofilm formation
- FIG. 17 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Vancomycin-resistant Enterococci (VRE) growth and biofilm formation
- VRE Vancomycin-resistant Enterococci
- FIG. 18 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Enterococcus faecalis growth and biofilm formation
- FIG. 19 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Proteus mirabilis growth and biofilm formation
- FIG. 20 is a bar graph showing the inhibitory effect of sodium citrate (3 mg/ml), EDTA (0.25 mg/ml) and ZnCl 2 (0.1 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Candida albicans growth and biofilm formation
- FIG. 21 is a bar graph showing the inhibitory effect of sodium citrate (1.5 mg/ml), EDTA (0.125 mg/ml) and ZnCl 2 (0.05 mg/ml) alone, and sodium citrate + EDTA, sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations on Malassezia pachydermatis growth and biofilm formation
- FIG. 22 is a bar graph showing the inhibitory effect of sodium citrate (1.5 mg/ml), EDTA (0.125 mg/ml) and ZnCl 2 (0.05 mg/ml) alone and in combination on Malassezia pachydermatis growth and biofilm formation DETAILED DESCRIPTION OF THE INVENTION
- antimicrobial refers to a compound or a composition that kills or inhibits or stops the growth of microorganisms, including, but not limited to bacteria and yeasts.
- biofilm refers to a structured community of microorganisms enclosed in a self produced extracellular polymeric matrix, and attached to a biotic or abiotic surface. Bacteria in a biofilm can be 1000 times more resistant to antibiotics/antimicrobials compared to their planktonic (free living) counterparts.
- biofilm formation refers to the attachment of microorganisms to surfaces and the subsequent development of multiple layers of cells.
- antibiofilm refers to inhibition of microbial biofilm formation and disruption or dispersal of preformed biofilms.
- infection refers to the invasion and multiplication of microorganisms such as bacteria, viruses, and parasites that are not normally present within the body.
- An infection may cause no symptoms and be subclinical, or it may cause symptoms and be clinically apparent.
- Microorganisms that live naturally in the body are not considered infections.
- personal care product refers to ophthalmic products, including eye drops, eyewash solution, contact lens care solution, contact lens cleaning solution, contact lens storing solution, contact lens disinfectant, contact lens cleaning-storing solution, and contact lens cleaning disinfecting-storing solution, contact lens containers, contact lenses, as well as podiatric, manicure and pedicure solutions, gels, creams, jellies, powders, pastes, lotions, soaps and cleaners, as well as hand washing containers, hand and foot scrubbers, cuticle soaking solutions, and foot washing containers.
- Disinfectants refers to substances that are applied to non-living objects to destroy microorganisms that are living on the objects. Disinfection does not necessarily kill all microorganisms, especially resistant bacterial spores; it is less effective than sterilization, which is an extreme physical and/or chemical process that kills all types of life. Disinfectants are different from other antimicrobial agents such as antibiotics, which destroy microorganisms within the body, and antiseptics, which destroy microorganisms on living tissue. Disinfectants are also different from biocides— the latter are intended to destroy all forms of life, not just microorganisms. Disinfectants work by destroying the cell wall /membrane of microbes or interfering with metabolism and growth.
- inhibitor refers to at least a decrease of the personal care products-associated bacterial growth and biofilm formation.
- prevention refers to at least preventing a condition associated with bacteria occurring in a mammal, particularly when the mammal is found to be predisposed to having the condition but has not yet been diagnosed as having it.
- a "preventative amount" as used herein includes a prophylactic amount, for example, an amount effective for preventing or protecting athe personal care products.
- a prophylactic amount for example, an amount effective for preventing or protecting athe personal care products.
- metal ion salt refers to salt of a metal ion such as zinc chloride, zinc lactate, zinc citrate, zinc gluconate, zinc sulfate zinc acetate, silver ion or silver sulfadiazine, silver sulfate, silver nitrate, and silver carbonate.
- the present invention may teach anti-infective compositions offering antimicrobials and antibiofilm activity, containing combinations of chelating agents with other antimicrobial agents, such as, for example, antimicrobials/antibiofilm compounds, metal ion salts with gelling agents, surfactants or stabilizing agents.
- Novel compositions that combine chelating agents together with metal ion salts such that lesser quantities of chelating agents and/or metal ion salts than would normally be necessary for an antimicrobial composition are used to achieve significant bacterial growth and biofilm inhibition. Higher concentrations of these compounds can be used if it is desired for certain applications.
- the amount of chelating agents to be used in the antimicrobial composition of this invention can be between 10000 to 100000 mg/L. The higher end of this stated range might be used to prepare a concentrated product that would be diluted prior to use.
- the amount of to be used in this invention is preferably between about 5000 to 10000 mg/L. Preferably, the range is between about 1000 to 5000 mg/L.
- the amount of chelating agents to be used should be between about 1000 to 5000 mg/L. The higher end of this range might apply if the compositions were formulated as a concentrate.
- the amount of chelating agent to be used in this invention is preferably between about 500 to 5000 mg/L. Preferably, the range is between about 1000 to 3000 mg/L, more preferably between about 2000 to 3000 mg/L.
- the disodium EDTA may be between about 10 mg/L - 50 mg/L of the composition
- sodium citrate may be between about 100 mg/L -500 mg/L of the composition
- zinc chloride or zinc citrate may be between about 1 mg/L- 10 mg/L.
- a two-component composition containing one or two chelating agents and a metal ion salt
- these compounds can be combined in the following manner: With good stirring, a chelating agent can be dissolved in water, followed by a metal ion salt. It should be noted, however, that the addition order can be reversed.
- a composition of the invention comprises: (a) a small amount of at least one or two chelating agent; (b) a small amount of a metal ion salt or iron-sequestering glycoprotein or antimicrobial peptide or an antibiotic or an antibiofilm compound; and (c) a sparing amount of at least one compound from the group consisting of a stabilizing agent and/or a gelling agent and /or a surfactant, wherein, the amount of each of component (a), (b) and (c) is sufficient to form, in combination, an effective anti-infective composition for the personal care products.
- concentration of active components in the compositions may vary as desired or necessary to decrease the amount of time the composition of the invention is used for the personal care products. These variations in active components concentration are easily determined by persons skilled in the art.
- the present invention may include unique and enhanced anti-infective compositions for the personal care products comprising at least two chelating agents and one metal ion salt.
- two chelating agents and a metal ion salt containing composition includes an antimicrobial compound.
- the chelating agents and a metal ion salt containing composition with an antimicrobial and/antibiofilm compound has an enhanced inhibitory effect on the personal care products- associated bacterial growth and biofilm formation.
- an enhanced antimicrobial-antibiofilm composition comprises at least one or two chelating agents, one metal ion salt and one or more antimicrobial agents comprising antiseptics (e.g., triclosan, chlorhexidine salt, cetylpyridinium chloride, etc.), antibiotics and bacteriocins (e.g., nisin, epidermin, gallidennin, cinnamycin, duramycin, lacticin 481, etc.), and iron- sequestering glycoproteins (ovotransferrin, lactoferrin and serrotransferrin).
- antiseptics e.g., triclosan, chlorhexidine salt, cetylpyridinium chloride, etc.
- antibiotics and bacteriocins e.g., nisin, epidermin, gallidennin, cinnamycin, duramycin, lacticin 481, etc.
- iron- sequestering glycoproteins ovotransferr
- the personal care product compositions may comprise ingredients such as citrate (e.g., citric acid, zinc citrate, sodium citrate, potassium citrate, etc.), minerals (e.g., mineral salts such as zinc chloride, zinc gluconate, zinc lactate, zinc citrate, zinc sulfate, zinc acetate, silver, silver sulfate, silver sulfadiazine, silver nitrate, silver carbonate, etc.), and triterpenoids (e.g., oleanolic acid and ursolic acid) and chitosan.
- citrate e.g., citric acid, zinc citrate, sodium citrate, potassium citrate, etc.
- minerals e.g., mineral salts such as zinc chloride, zinc gluconate, zinc lactate, zinc citrate, zinc sulfate, zinc acetate, silver, silver sulfate, silver sulfadiazine, silver nitrate, silver carbonate, etc.
- triterpenoids e.
- a composition comprises an antibiotic and one or two chelating agents and also one metal ion salt.
- Antibiotics are well known. Groups of antibiotics include, but are not limited to, ⁇ -lactam inhibitors (e.g., penicillin, ampicillin, amoxicillin, methicillin, etc.), cephalosporins (e.g., cephalothin, cephamycin, etc.), aminoglycosides (e.g., streptomycin, tobramycin, etc.), polyenes (e.g., amphotericin, nystatin, etc.), macrolides (e.g., erythromycin, etc.), tetracyclines (e.g., tetracycline, doxycycline, etc.), nitroimidazole (e.g., metronidazole), quinolones (e.g., nalidixic acid), rifamycins (e.g., rifampin
- a composition comprises an antiseptic, one or two chelating agents and one metal ion salt.
- Antiseptics are agents that kill or inhibit the growth of microorganisms on the external surfaces of the body.
- Antiseptics include, but are not limited to, triclosan, chlorhexidine salt, and cetylpyridinium chloride.
- a composition comprises an antibiofilm compound, one or two chelating agents and a metal ion salt.
- Antibiofilm compounds include, but not limited to, DisperinB, DNase I, Proteinase K, apyrase, cis-2-decenoic acid, alginate lyase, lactoferrin, gallium, cellulase, and 5-fluorouracil.
- a composition is effective for inhibiting growth and biofilm formation in the personal care products.
- the composition is also effective in disrupting or dispersing preformed biofilms, which makes biofilm-embedded bacteria more susceptible to antimicrobial killing. Under appropriate environmental conditions, such as moisture and pH, infections can be modulated using embodiments of the invention.
- An embodiment of the invention may also include other personal care acceptable vehicles, diluents, and additives such as antioxidants, antiinflammatory compounds, vitamins, tissue degrading enzymes, buffers and solutes that render the formulation isotonic in the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents, surfactants and thickening agents.
- other personal care acceptable vehicles diluents, and additives
- antioxidants such as antioxidants, antiinflammatory compounds, vitamins, tissue degrading enzymes, buffers and solutes that render the formulation isotonic in the intended recipient
- aqueous and non-aqueous sterile suspensions which may include suspending agents, surfactants and thickening agents.
- a composition of the invention may be added to a variety of formulations suitable for apply ing/delivering the composition to the personal care products, including, but not limited to, disinfecting solutions, lotions, creams, gels, sprays. To provide such formulations, a composition of this invention is combined with one or more personal care acceptable excipients.
- Formulations including, but not limited to, personal care acceptable compositions comprising one or two chelating agents and a metal ion salt in combination with an antiseptic, an antibiotic, an antimicrobial, an iron- sequestering glycoprotein, a bacteriocin, extracellular matrix or chitosan can be prepared by any known method.
- methods of manufacturing anti-infective compositions may comprise combining a personal care acceptable carrier and an effective amount of both chelating agents and a metal ion salt with an antiseptic, an antibiotic, a bacteriocin, an antimicrobial peptide or chitosan.
- Such personal care acceptable vehicles include, but are not limited to, water, ethanol, humectants such as polypropylene glycol, glycerol and sorbitol, gelling agents such as cellulose derivatives, polyoxypropylene/polyoxyethylene block copolymers, carboxy methyl cellulose, pluronic F-127, sodium alginate, polyethylene glycol, thickening agents such as CarbopolTM 934.
- preferred concentration range of ingredients may include: (i) Sodium Citrate: (a) 50,000 mg/L -100,000 mg/L, (b) 25,000 mg/L- 50,000 mg/L, (c) 10,000 mg/L - 25,000 mg/L, (d) 5,000 mg/L -10,000 mg/L, & (e) 1, 000 mg/L - 5, 000 mg/L.
- Disodium EDTA (a) 10,000 mg/L - 25,000 mg/L, (b) 5,000 mg/L-10,000 mg/L, (c) 1,000 mg/L-5,000 mg/L, (d) 500 mg/L -1,000 mg/L, & (e) 100 mg/L -500 mg/L
- one or more chelating agents and a metal ion salt together is formulated as personal care acceptable medicament as described herein comprising a carrier and an effective amount of composition comprising one or more chelating agents and a metal ion salt as active ingredients.
- an enhanced personal care product does not present any antibiotic resistance concerns and bio-compatibility/ safety issues.
- the composition of this invention comprising one or two chelating agents (EDTA and sodium citrate) and a metal ion salt (zinc chloride or zinc sulfate or zinc lactate) has GRAS (Generally Recognized as Safe) status and all these ingredients are food as well as feed additives.
- Example 1 Inhibitory effect of Sodium Citrate. EDTA and Zinc Chloride alone and in combination on methicillin-resistant Staphylococcus aureus (MRSA) growth and bio film formation.
- MRSA methicillin-resistant Staphylococcus aureus
- a composition comprising sodium citrate, EDTA and zinc chloride showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA, or zinc chloride alone (FIG. 1).
- Example 2 Inhibitory effect of Sodium Citrate. EDTA and Zinc Chloride alone, and in combination on methicillin-resistant Staphylococcus pseudintermedius (MRSP) growth and biofilm formation
- a composition comprising sodium citrate, EDTA and zinc chloride showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA, or zinc chloride alone (FIG. 2).
- Example 3 Inhibitory effect of Sodium Citrate. EDTA. and Zinc Chloride alone, and in combination on Pseudomonas aeruginosa growth and biofilm formation
- a composition comprising sodium citrate, EDTA and zinc chloride showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA, or zinc chloride alone (FIG. 3).
- Example 4 Inhibitory effect of Sodium Citrate. EDTA. and Zinc Chloride alone and in combination on Listeria monocytogenes growth and biofilm formation
- a composition comprising sodium citrate, EDTA and zinc chloride showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA, or zinc chloride alone (FIG. 4).
- Example 5 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and
- Sodium citrate + EDTA Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on methicillin-resistant Staphylococcus aureus [MRSA] growth and biofilm formation
- MRSA methicillin-resistant Staphylococcus aureus
- An overnight broth culture of S. aureus (MRSA) was grown in TSB and used as inoculum.
- 96-well microplates containing TSB in the absence and the presence of each compound (sodium citrate or EDTA or Zinc chloride) separately and Sodium citrate + EDTA, Sodium citrate + ZnCl 2 , and EDTA + ZnCl 2 combinations were inoculated and incubated at 37°C for 24 hours.
- Example 6 Effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium
- Citrate + EDTA Sodium Citrate + ZnCl?. and EDTA + ZnCl? combinations on methicillin resistant Staphylococcus pseudintermedius (MRSP) growth and biofilm formation
- Example 7 Inhibitory effect of Sodium Citrate. EDTA. and ZnCl? alone, and Sodium Citrate + EDTA. Sodium Citrate + ZnCl?. and EDTA + ZnCl? combinations on Pseudomonas aeruginosa growth and biofilm formation
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a Sodium citrate + EDTA, and EDTA +ZnCl 2 combinations showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA, or zinc chloride alone (FIG. 7).
- Example 8 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Salmonella choleraesuis ATCC 10708
- Example 9 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Escherichia coli Q157:H7
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a Sodium citrate + EDTA, Sodium citrate + ZnC12, and EDTA + ZnC12 combinations showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA or zinc chloride alone (FIG. 9).
- Example 10 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and in combination on Escherichia coli Q157:H7
- Example 11 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Staphylococcus epidermidis
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a Sodium citrate + EDTA combination showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA alone (FIG. 11).
- Example 12 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on coagulase-negative Staphylococci (CoNS-42)
- Example 13 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Streptococcus agalactiae ATCC 12386
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a Sodium citrate + EDTA combination showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA alone (FIG. 13).
- Example 14 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Klebsiella pneumoniae
- Example 15 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Acinetobacter baumannii
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a Sodium citrate + EDTA combination showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA alone (FIG. 15).
- Example 16 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Stenotrophomonas maltophilia
- Example 17 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Vancomycin-resistant Enterococci (VRE)
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a Sodium citrate + EDTA combination showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA alone (FIG. 17).
- Example 18 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Enter ococcus faecalis
- Example 19 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Proteus mirabilis
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a Sodium citrate + EDTA combination showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA alone (FIG. 19).
- Example 20 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Candida albicans
- Example 21 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone, and Sodium citrate + EDTA. Sodium citrate + ZnCl?. and EDTA + ZnCl? combinations on Malassezia pachydermatis
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a Sodium citrate + EDTA, Sodium citrate + ZnC12, and EDTA + ZnC12 combinations showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA or zinc chloride alone (FIG. 21).
- Example 22 Inhibitory effect of Sodium Citrate. EDTA and ZnCl? alone and in combination on Malassezia pachydermatis
- the dye was then solubilized with 33% acetic acid, and absorbance at 630 nm was determined using a microtiter plate reader.
- a composition comprising sodium citrate, EDTA, and ZnCl 2 showed an enhanced inhibitory effect on biofilm formation, as compared to sodium citrate, or EDTA, or zinc chloride alone (FIG. 22).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580045752.2A CN106572662A (en) | 2014-06-27 | 2015-06-26 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
DK15810908.2T DK3160234T3 (en) | 2014-06-27 | 2015-06-26 | Composition for use in the prevention and treatment of ophthalmic, hand or foot biofilm growth |
AU2015281753A AU2015281753A1 (en) | 2014-06-27 | 2015-06-26 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
US15/322,385 US11103433B2 (en) | 2012-06-27 | 2015-06-26 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
ES15810908T ES2896402T3 (en) | 2014-06-27 | 2015-06-26 | Compositions for use in preventing and treating the growth of ophthalmic, hand or foot biofilms |
PL15810908T PL3160234T3 (en) | 2014-06-27 | 2015-06-26 | Compositions for use in preventing and treating opthalmic, hand or feet biofilm growth |
CA2953401A CA2953401A1 (en) | 2014-06-27 | 2015-06-26 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
KR1020177002567A KR20170024070A (en) | 2014-06-27 | 2015-06-26 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
EP15810908.2A EP3160234B1 (en) | 2014-06-27 | 2015-06-26 | Compositions for use in preventing and treating opthalmic, hand or feet biofilm growth |
JP2016575383A JP2017519035A (en) | 2014-06-27 | 2015-06-26 | Antimicrobial-antibiofilm composition and use of the composition for personal care products |
US17/392,603 US11723852B2 (en) | 2011-10-31 | 2021-08-03 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462018114P | 2014-06-27 | 2014-06-27 | |
US62/018,114 | 2014-06-27 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2012/050432 Continuation-In-Part WO2013063695A1 (en) | 2011-10-31 | 2012-06-27 | Compositions and methods for preventing and treating oral diseases |
US14/355,308 Continuation-In-Part US11090366B2 (en) | 2011-10-31 | 2012-06-27 | Compositions and methods for reducing oral biofilm |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14355308 A-371-Of-International | 2014-10-07 | ||
US15/322,385 A-371-Of-International US11103433B2 (en) | 2012-06-27 | 2015-06-26 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
US15322385 Continuation-In-Part | 2016-12-27 | ||
US17/392,603 Continuation US11723852B2 (en) | 2011-10-31 | 2021-08-03 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015196299A1 true WO2015196299A1 (en) | 2015-12-30 |
Family
ID=54936394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2015/050599 WO2015196299A1 (en) | 2011-10-31 | 2015-06-26 | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
Country Status (11)
Country | Link |
---|---|
US (1) | US11103433B2 (en) |
EP (1) | EP3160234B1 (en) |
JP (1) | JP2017519035A (en) |
KR (1) | KR20170024070A (en) |
CN (1) | CN106572662A (en) |
AU (1) | AU2015281753A1 (en) |
CA (1) | CA2953401A1 (en) |
DK (1) | DK3160234T3 (en) |
ES (1) | ES2896402T3 (en) |
PL (1) | PL3160234T3 (en) |
WO (1) | WO2015196299A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108477209A (en) * | 2018-05-30 | 2018-09-04 | 军事科学院系统工程研究院卫勤保障技术研究所 | A kind of thimerosal and preparation method thereof |
US10626354B2 (en) | 2016-04-29 | 2020-04-21 | Novozymes A/S | Detergent compositions and uses thereof |
RU2725991C1 (en) * | 2020-04-24 | 2020-07-08 | Общество с ограниченной ответственностью «РОСБИО» | Liquid disinfectant and antiseptic composition for use in medicine and veterinary science |
US10954478B2 (en) | 2016-04-29 | 2021-03-23 | Novozymes A/S | Detergent compositions and uses thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
US11723852B2 (en) | 2011-10-31 | 2023-08-15 | Kane Biotech Inc. | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
CN111778117A (en) * | 2019-05-21 | 2020-10-16 | 何凡 | Preparation method of antiviral biological peptide care solution |
CN110292662B (en) * | 2019-08-11 | 2022-02-08 | 上海鹏冠生物医药科技有限公司 | Antibacterial liquid for urinary tract irrigation and preparation method thereof |
CN111254100A (en) * | 2020-03-27 | 2020-06-09 | 山东中医药高等专科学校 | Pseudomonas aeruginosa biofilm and preparation method and application thereof |
WO2022266943A1 (en) * | 2021-06-24 | 2022-12-29 | L'oreal | Composition for cleansing and/or removing makeups from keratin materials |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003047341A2 (en) * | 2001-12-05 | 2003-06-12 | Aseptica, Inc. | Anti-microbial systems and methods |
WO2005097067A1 (en) * | 2004-03-29 | 2005-10-20 | Bausch & Lomb Incorporated | Zinc preservative composition and method of use |
WO2013063695A1 (en) | 2011-10-31 | 2013-05-10 | Kane Biotech Inc. | Compositions and methods for preventing and treating oral diseases |
WO2014100777A2 (en) * | 2012-12-20 | 2014-06-26 | Rajiv Bhushan | Antimicrobial compositions |
WO2014134701A1 (en) * | 2013-03-07 | 2014-09-12 | Kane Biotech Inc. | Antimicrobial-antibiofilm compositions and methods of use thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4060600A (en) | 1972-10-26 | 1977-11-29 | National Patent Development Corporation | Treating teeth |
US3887712A (en) | 1973-06-15 | 1975-06-03 | Merck & Co Inc | Oral hygiene products |
GB1524325A (en) | 1976-03-18 | 1978-09-13 | Ferrosan Ab | Piperidine derivatives |
US4160821A (en) | 1978-02-27 | 1979-07-10 | Johnson & Johnson | Treatment for gingivitis |
US4178363A (en) | 1978-05-09 | 1979-12-11 | Miller Taylor C Jr | Method for reducing dental plaque and pellicle precursor of plaque |
US4999184A (en) | 1982-06-22 | 1991-03-12 | The Procter & Gamble Company | Oral compositions |
US4610871A (en) | 1984-12-21 | 1986-09-09 | Ici Americas Inc. | Dentifrice formulation and method of treating teeth, mouth and throat therewith to reduce plaque accumulation and irritation |
US5310546A (en) | 1990-02-07 | 1994-05-10 | 7-L Corporation | Mouthrinse and method of preparation |
US5174990A (en) | 1990-02-07 | 1992-12-29 | 7-L Corporation | Mouthrinse and method of preparation |
US5104644A (en) | 1990-02-07 | 1992-04-14 | 7-L Corporation | Mouthrinse composition |
ZA94438B (en) | 1993-02-19 | 1994-08-29 | Warner Lambert Co | Pre-brushing rinse composition |
US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
KR20010013377A (en) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | Mild, leave-on antimicrobial compositions |
US6475771B1 (en) | 1997-06-10 | 2002-11-05 | University Of Florida Research Foundation | Antimicrobial polypeptides and methods of use |
US5932469A (en) | 1997-06-10 | 1999-08-03 | University Of Florida | Antimicrobial polypeptide, nucleic acid, and methods of use |
US6218362B1 (en) | 1997-09-08 | 2001-04-17 | Universite Laval | Lantibiotic from Streptococcus mutans and uses thereof |
US6342385B1 (en) | 2000-07-28 | 2002-01-29 | The Uab Research Foundation | Mutacin I biosynthesis genes and proteins |
US6589562B1 (en) | 2000-10-25 | 2003-07-08 | Salvona L.L.C. | Multicomponent biodegradable bioadhesive controlled release system for oral care products |
US7597895B2 (en) | 2001-02-20 | 2009-10-06 | The Governing Council Of The University Of Toronto | Signal peptides, nucleic acid molecules and methods for treatment of caries |
US6696047B2 (en) | 2001-09-13 | 2004-02-24 | The Procter & Gamble Company | Stable oral care compositions comprising chlorite |
US8541472B2 (en) * | 2001-12-05 | 2013-09-24 | Aseptica, Inc. | Antiseptic compositions, methods and systems |
WO2008043175A1 (en) * | 2006-10-13 | 2008-04-17 | Kane Biotech Inc. | SOLUBLE β-N-ACETYLGLUCOSAMINIDASE BASED ANTIBIOFILM COMPOSITIONS AND USES THEREOF |
TWI322828B (en) * | 2002-12-23 | 2010-04-01 | Alcon Inc | Use of multifunctional surface active agents to clean contact lenses |
ES2214135B1 (en) | 2003-02-21 | 2005-05-01 | Laboratorios Kin S.A. | COMPOSITION FOR THE TREATMENT OF ORAL CAVITY AND CORRESPONDING USE. |
US20050101605A1 (en) | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
US20050170013A1 (en) * | 2004-02-04 | 2005-08-04 | Douglas Jerry A. | Composition for treating a dermatological inflammatory response and method of preparation thereof |
US20060134020A1 (en) | 2004-12-21 | 2006-06-22 | Robinson Richard S | Anti-caries oral care composition with a chelating agent |
WO2006089139A2 (en) | 2005-02-15 | 2006-08-24 | Lab39, Llc | Oral care cleaning compositions and methods |
AU2006330769A1 (en) * | 2005-12-29 | 2007-07-05 | Kansas State University Research Foundation | Antimicrobial cathelicidin peptides |
US20070190005A1 (en) * | 2006-02-14 | 2007-08-16 | Playtex Products, Inc. | Synergistic preservative systems and their use in cosmetic compositions |
US8346353B2 (en) | 2007-04-24 | 2013-01-01 | St. Jude Medical Ab | Implantable medical system for detecting incipient edema |
DE102007030931A1 (en) * | 2007-07-03 | 2009-01-08 | Birgit Riesinger | Composition containing at least one nutritive, at least one disinfecting or decontaminating and / or at least one protease inhibiting active substance and / or active substance complex |
US9072868B2 (en) * | 2008-10-27 | 2015-07-07 | Pursuit Vascular, Inc. | Device for delivery of antimicrobial agent into trans-dermal catheter |
CN101756794A (en) | 2008-11-18 | 2010-06-30 | 陈恩平 | Zinc chloride mouth wash for preventing dental plaque and gingivitis |
WO2009101216A2 (en) * | 2009-04-28 | 2009-08-20 | Symrise Gmbh & Co. Kg | Omega-cyclohexylalkan-1-oles and use thereof as antimicrobial actives to combat body odor |
WO2014134731A1 (en) * | 2013-03-07 | 2014-09-12 | Kane Biotech Inc. | Antimicrobial-antibiofilm compositions and methods of use thereof |
US10357470B2 (en) * | 2013-03-07 | 2019-07-23 | Kane Biotech Inc. | Antimicrobial-antibiofilm compositions and methods of use thereof |
WO2014160579A1 (en) * | 2013-03-25 | 2014-10-02 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2015
- 2015-06-26 JP JP2016575383A patent/JP2017519035A/en active Pending
- 2015-06-26 US US15/322,385 patent/US11103433B2/en active Active
- 2015-06-26 ES ES15810908T patent/ES2896402T3/en active Active
- 2015-06-26 CN CN201580045752.2A patent/CN106572662A/en active Pending
- 2015-06-26 KR KR1020177002567A patent/KR20170024070A/en unknown
- 2015-06-26 PL PL15810908T patent/PL3160234T3/en unknown
- 2015-06-26 DK DK15810908.2T patent/DK3160234T3/en active
- 2015-06-26 WO PCT/CA2015/050599 patent/WO2015196299A1/en active Application Filing
- 2015-06-26 CA CA2953401A patent/CA2953401A1/en not_active Abandoned
- 2015-06-26 AU AU2015281753A patent/AU2015281753A1/en not_active Abandoned
- 2015-06-26 EP EP15810908.2A patent/EP3160234B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003047341A2 (en) * | 2001-12-05 | 2003-06-12 | Aseptica, Inc. | Anti-microbial systems and methods |
WO2005097067A1 (en) * | 2004-03-29 | 2005-10-20 | Bausch & Lomb Incorporated | Zinc preservative composition and method of use |
WO2013063695A1 (en) | 2011-10-31 | 2013-05-10 | Kane Biotech Inc. | Compositions and methods for preventing and treating oral diseases |
WO2014100777A2 (en) * | 2012-12-20 | 2014-06-26 | Rajiv Bhushan | Antimicrobial compositions |
WO2014134701A1 (en) * | 2013-03-07 | 2014-09-12 | Kane Biotech Inc. | Antimicrobial-antibiofilm compositions and methods of use thereof |
Non-Patent Citations (2)
Title |
---|
R.M.Q. SHANKS ET AL.: "Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces", NEPHROL. DIAL TRANSPLANT, vol. 21, no. 8, 20 April 2006 (2006-04-20), pages 2247 - 2255, XP055019128, ISSN: 0931-0509 * |
See also references of EP3160234A4 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10626354B2 (en) | 2016-04-29 | 2020-04-21 | Novozymes A/S | Detergent compositions and uses thereof |
US10954478B2 (en) | 2016-04-29 | 2021-03-23 | Novozymes A/S | Detergent compositions and uses thereof |
US11326130B2 (en) | 2016-04-29 | 2022-05-10 | Novozymes A/S | Detergent compositions and uses thereof |
US11680231B2 (en) | 2016-04-29 | 2023-06-20 | Novozymes A/S | Detergent compositions and uses thereof |
CN108477209A (en) * | 2018-05-30 | 2018-09-04 | 军事科学院系统工程研究院卫勤保障技术研究所 | A kind of thimerosal and preparation method thereof |
CN108477209B (en) * | 2018-05-30 | 2021-01-15 | 军事科学院系统工程研究院卫勤保障技术研究所 | Disinfectant and preparation method thereof |
RU2725991C1 (en) * | 2020-04-24 | 2020-07-08 | Общество с ограниченной ответственностью «РОСБИО» | Liquid disinfectant and antiseptic composition for use in medicine and veterinary science |
Also Published As
Publication number | Publication date |
---|---|
US20190076345A9 (en) | 2019-03-14 |
CA2953401A1 (en) | 2015-12-30 |
DK3160234T3 (en) | 2021-11-08 |
US20170128338A1 (en) | 2017-05-11 |
EP3160234B1 (en) | 2021-08-04 |
EP3160234A1 (en) | 2017-05-03 |
JP2017519035A (en) | 2017-07-13 |
PL3160234T3 (en) | 2022-02-21 |
US11103433B2 (en) | 2021-08-31 |
AU2015281753A1 (en) | 2017-02-02 |
KR20170024070A (en) | 2017-03-06 |
EP3160234A4 (en) | 2018-01-24 |
CN106572662A (en) | 2017-04-19 |
ES2896402T3 (en) | 2022-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11103433B2 (en) | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products | |
US9980497B2 (en) | Antimicrobial-antibiofilm compositions and methods of use thereof | |
US10827749B2 (en) | Compositions and methods with efficacy against spores and other organisms | |
US10357470B2 (en) | Antimicrobial-antibiofilm compositions and methods of use thereof | |
WO2014134701A1 (en) | Antimicrobial-antibiofilm compositions and methods of use thereof | |
US4814334A (en) | Composition with high bactericidal power containing a biguanide and a pyrimidine | |
US20110212187A1 (en) | Antimicrobial composition | |
US10405545B2 (en) | Compositions and methods having improved efficacy against spores and other organisms | |
US11723852B2 (en) | Antimicrobial-antibiofilm compositions and methods of use thereof for personal care products | |
Rodrigues et al. | Disinfectants to fight oral candida biofilms | |
KR101350442B1 (en) | A stable antimicrobial and antiseptic aqueous composition containing chlorhexidine | |
ES2300217A1 (en) | Iodophor composition for treating udder in mammals after milking, comprises povidone iodine and iodized component, where series of redox reactions and complexing with alcohol ethoxylates is carried out in acidic medium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15810908 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2953401 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016575383 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15322385 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20177002567 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015810908 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015810908 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015281753 Country of ref document: AU Date of ref document: 20150626 Kind code of ref document: A |